TTPNetwork’s response to the NICE Decision on the use of Caplacizumab in the treatment of TTP
TTPNetwork’s response to the NICE Decision on the use of Caplacizumab in the treatment of…
Read more
TTPNetwork supports patients with the condition Thrombotic Thrombocytopenic Purpura (TTP).
We also support family, friends and medical staff. We are UK based but we have visitors from around the world.
On this site you will find information and sources of help for TTP, including documents to help when travelling abroad, links to best practice guidelines and the opportunity to make contact with others dealing with TTP.
Our Aims
Providing
Information
Patient
Network
Patient
Champions
Featured Posts
Latest Articles
TTPNetwork’s response to the NICE Decision on the use of Caplacizumab in the treatment of TTP
TTPNetwork’s response to the NICE Decision on the use of Caplacizumab in the treatment of TTP Nice have today published the following decision: Caplacizumab with plasma exchange and immunosuppression is recommended, within its marketing authorisation, as an option for treating an acute episode of acquired thrombotic thrombocytopenic purpura (TTP) in adults, and in young people…
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group
Pregnancy and postpartum are high-risk periods for different forms of thrombotic microangiopathy (TMA). However, the management of pregnancy-associated TMA remains ill-defined…
Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombomicroangiopathy caused by deficiency of ADAMTS13. Acute neurological involvement is well described, but its long‐term impact requires evaluation. One‐hundred thirty‐one patients, following an acute TTP event, with severe headache or neurological symptoms had a cerebral MRI…